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Abstract
Background The outcomes of minimally invasive pancreaticoduodenectomy have not been adequately compared with those 
of open pancreaticoduodenectomy in patients with pancreatic ductal adenocarcinoma. We performed a meta‐analysis to com-
pare the perioperative and oncological outcomes of these two pancreaticoduodenectomy procedures specifically in patients 
with pancreatic ductal adenocarcinoma.
Methods Before this study was initiated, a specific protocol was designed and has been registered in PROSEPRO (ID: 
CRD42020149438). Using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, 
PubMed, EMBASE, Web of Science, Cochrane Central Register, and ClinicalTrials.gov databases were systematically 
searched for studies published between January 1994 and October 2019. Overall survival, disease-free survival, and time 
to commencing adjuvant chemotherapy were the primary endpoint measurements, whereas perioperative and short-term 
outcomes were the secondary endpoints.
Results The final analysis included 9 retrospective cohorts comprising 11,242 patients (1377 who underwent minimally 
invasive pancreaticoduodenectomy and 9865 who underwent open pancreaticoduodenectomy). There were no significant 
differences in the patients’ overall survival, operative time, postoperative complications, 30-day mortality, rate of vein 
resection, number of harvested lymph nodes, or rate of positive lymph nodes between the two approaches. However, disease-
free survival, time to starting adjuvant chemotherapy, length of hospital stay, and rate of negative margins in patients who 
underwent minimally invasive pancreaticoduodenectomy showed improvements relative to those in patients who underwent 
open surgery.
Conclusions Minimally invasive pancreaticoduodenectomy provides similar or even improved perioperative, short-term, and 
long-term oncological outcomes when compared with open pancreaticoduodenectomy for patients with pancreatic ductal 
adenocarcinoma.
Keywords Pancreatic ductal carcinoma · Pancreaticoduodenectomy · Laparoscopic surgery · Robotic surgical procedures · 
Minimally invasive surgery · Meta-analysis
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[1]. Despite the application of various neoadjuvant and 
adjuvant treatment protocols, pancreaticoduodenectomy 
(PD) remains the only curative treatment for patients with 
adenocarcinoma of the pancreatic head. PD is one of the 
most complex procedures in gastroenterological surgery, 
and requires extensive visceral organ dissection and com-
plex reconstructive digestive anastomoses; therefore, it is 
normally performed using an open approach.
The first laparoscopic PD (LPD) was reported by Gagner 
and Pomp in 1994 [2], while the first robotic PD (RPD) was 
described by Giulianotti et al. in 2003 [3]. Since then, mini-
mally invasive PD (MIPD), which encompasses LPD and 
RPD, is increasingly used worldwide; however, it remains a 
challenging procedure because of the technical limitations 
of laparoscopy or robot control as well as the steep learn-
ing curve when training physicians. Therefore, the feasibil-
ity and safety of the minimally invasive approach remain 
controversial.
Recent studies [4, 5] and meta-analyses [6, 7] showed 
that the outcomes of MIPD were similar to or more favora-
ble than open PD (OPD) with respect to the incidence of 
postoperative morbidity, short-term oncologic outcomes, 
and long-term overall survival rates. Furthermore, MIPD 
is associated with lower estimated intraoperative blood 
loss, shorter length of hospital stay (LOS), higher rate of 
R0 resection, and the harvesting of a greater number of 
lymph nodes. However, these studies involved patients with 
a variety of disease histologies; therefore, objective conclu-
sions regarding the oncologic outcomes of patients with this 
malignancy, especially PDAC, were unclear. Other related 
meta-analyses [8, 9] involved relatively few patients with 
PDAC. According to our search, no meta-analysis was per-
formed specifically to investigate the perioperative, short-
term, and long-term oncological outcomes of patients who 
underwent MIPD for PDAC. In this study, we carefully 
screened and selected studies that specifically investigated 
patients with PDAC. The aim of our meta-analysis was to 
meaningfully assess the perioperative, short-term, and long-
term oncologic outcomes of these patients, with the primary 
investigative endpoints being overall survival (OS), disease-
free survival (DFS), and the time to starting postsurgical 
adjuvant chemotherapy.
Materials and methods
Before this study was initiated, we designed a specific pro-
tocol which has been registered in PROSEPRO. The ID is 
CRD42020149438 (details of registration is included in 
Supplementary Materials). Thus, this study was performed 
in accordance with the recommendations of the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) guidelines [10]. This article does not contain 
any studies with human participants performed by any of 
the authors; therefore, there was no requirement for IRB 
approval.
Data sources and search methods
We systematically searched the PubMed, EMBASE, Web of 
Science, Cochrane Central Register, and ClinicalTrials.gov 
databases for studies published in English between 1994 and 
October 2019. The search Medical Subject Heading (MeSH) 
terms were “laparoscopic pancreaticoduodenectomy” OR 
“robotic pancreaticoduodenectomy” AND “pancreatic ductal 
adenocarcinoma,” as well as all associated entry words 
retrieved using the MeSH index (details of our search strat-
egy are included in Supplementary Materials). There was 
no language restriction. We also reviewed the introduction 
and discussion sections of the retrieved manuscripts, rel-
evant review articles, and published meta-analyses to iden-
tify additional trials. Two authors (Rui Sun and Jiawen Yu) 
independently conducted the literature search, screened the 
abstracts, and selected the relevant trials.
Inclusion criteria
Studies published between January 1994 and October 2019 
were considered eligible if they met the following inclusion 
criteria: (1) the investigated population comprised patients 
with PDAC; (2) the interventions compared were LPD or 
RPD versus OPD; and (3) the study investigated at least one 
of the following outcomes: operative time, intraoperative 
blood transfusion, postoperative morbidity and mortality, 
LOS, rate of vein and R0 resection, number of lymph nodes 
retrieved, time to starting adjuvant treatment, DFS, and OS.
Exclusion criteria
The exclusion criteria are as follows: (1) review articles; 
(2) meeting abstracts; (3) irrelevant studies such as those 
that investigated only a single surgical technique; (4) insuf-
ficient information available in the English abstract; (5) stud-
ies with no comparative data; and (6) studies without PDAC 
data. If papers had overlapping data, those describing the 
smaller-scale studies were excluded.
Quality assessment
We adopted the Newcastle–Ottawa Scale (NOS) [11], which 
is designed specifically for observational investigations, to 
assess the quality of the selected studies. The NOS focuses 
on 3 separate sections of a case–control or cohort study, with 
the number of stars representing the assessment score. The 
maximum achievable score under the NOS is 9 stars, includ-
ing 4 for the selection process, 2 for comparability, and 3 for 
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exposure and outcome. A score of ≥ 6 stars is considered 
indicative of high quality. Two investigators independently 
assessed the selected studies.
Data extraction
Two investigators independently extracted the following 
information: first author, year of publication, study type, 
mean age, population size, tumor size, and main outcomes; 
the latter included operative time, intraoperative blood trans-
fusion, postoperative morbidity and mortality, LOS, rate of 
vein and R0 resection, number of lymph nodes retrieved, 
time to adjuvant treatment, DFS, and OS. The evaluators 
resolved any disputes via consensus during the screening 
processes.
Statistical analysis
Statistical analyses were conducted using Review Manager 
5.3 (Cochrane Collaboration). The relative risk (RR) and 
mean difference (MD) with the 95% confidence interval 
(CI) were used as the measures of dichotomous and con-
tinuous variables, respectively. Natural logarithm hazard 
ratios (HRs) and standard errors were used as summary 
statistics for DFS and OS data. Using the methods of Wan 
et al. [12] and Luo et al. [13], medians with ranges as well 
as the mid-quartile range were converted into means with 
standard deviations. For studies in which natural logarithm 
HRs and standard errors or corresponding 95% CIs were not 
available, estimates from the published survival curves were 
calculated using the method suggested by Tierney et al. [14]. 
P-values less than 0.05 indicated statistical significance. 
Heterogeneity was quantified by the I2 statistic; a study with 
an I2 less than 50% was considered to have no heterogene-
ity, and the fixed effects model was then applied to pool the 
results; otherwise, the random effects model was used.
Results
Search results and characteristics of the included 
studies
A flowchart of our analysis protocol is shown in Fig. 1. Our 
analysis included 9 retrospective cohort studies [15–23] 
comparing MIPD and OPD in a total of 11,242 patients with 
PDAC (1377 and 9865 underwent MIPD and OPD, respec-
tively). The characteristics and qualities of these 9 studies 
are listed in Table 1, while the main results are shown in 
Table 2. All the analysis results including operative time, 
intraoperative blood transfusion, LOS, postoperative compli-
cations and mortality, and short- and long-term oncological 
outcomes are shown in Figs. 2, 3, 4, and 5. Among the 9 
studies, 8 [15, 17–23] compared LPD and OPD and only 1 
[16] compared RPD and OPD. The means of the patients’ 
ages in each study ranged from 65.4 to 79.6 years with a 
majority in both the MIPD and OPD cohorts being of com-
parable age; only patients of both groups in Chapman et al.’s 
study (79.6 versus 79.6 years; P = 0.99) [22] were older than 
those in other studies. There were no significant differences 




Three studies [15, 21, 23] that encompassed 913 patients 
investigated operative times (including 228 and 685 patients 
who underwent MIPD and OPD, respectively). The opera-
tive time was longer for the MIPD group in 2 of these stud-
ies, and was longer for the OPD group in the third. The 
pooled estimates of these studies showed that the duration 
of surgery was not significantly different between the MIPD 
and OPD groups (MD 50.09; 95% CI − 25.21 to 125.38; 
P = 0.11). The analysis found statistically significant hetero-
geneity (I2 = 97%); thus, a random effects model was adopted 
(Fig. 2A). No differences in the results and no heterogeneity 
were found on sensitivity analysis.
Intraoperative blood transfusion
Three studies encompassing 913 patients (228 who under-
went MIPD and 685 who underwent OPD) compared intra-
operative blood transfusion rates [15, 21, 23]. The pooled 
results showed a higher rate of intraoperative blood transfu-
sion in the OPD group; the pooled RR (0.58; 95% CI 0.44 to 
0.77; P = 0.0002) showed a significant difference in the intra-
operative blood transfusion rate between the two groups. 
Heterogeneity was not significant (I2 = 0%) (Fig. 2B).
LOS
Six trials [15, 17, 20–23] with a total of 10,863 patients 
(1319 and 9544 who underwent MIPD and OPD, respec-
tively) investigated the LOS. Five studies showed the LOS to 
be significantly lower in the MIPD group, whereas 1 showed 
it to be lower in the OPD group. The analysis found signifi-
cant heterogeneity (I2 = 98%), and a random effects model 
was adopted. The pooled mean difference (MD = − 4.66; 
95% CI − 9.13 to − 0.19; P = 0.04) indicated a significantly 
shorter LOS in the MIPD group (Fig. 2C). The results and 
heterogeneity were not significantly different in the sensitiv-
ity analysis.
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Postoperative complications and 30‑day mortality
Four studies that included 942 patients combined (243 
who underwent MIPD and 699 who underwent OPD) [15, 
17, 21, 23] examined surgical complications. The pooled 
surgical complication data revealed no difference between 
MIPD and OPD (RR = 0.84; 95% CI 0.67 to 1.05; P = 0.12, 
I2 = 45%) (Fig. 3A). A lack of significant differences was 
also observed on subgroup analyses of postoperative pan-
creatic fistulae (3 studies [15, 17, 21], RR = 0.91; 95% CI, 
0.56 to 1.46; P = 0.69, I2 = 0%) (Fig. 3B), delayed gastric 
emptying (3 studies [15, 17, 21], RR = 0.86; 95% CI, 0.33 
to 2.28; P = 0.77, I2 = 67%) (Fig. 3C), and postpancrea-
tectomy hemorrhage (3 studies [15, 17, 21], RR = 1.33; 
95% CI 0.68 to 2.58; P = 0.4, I2 = 0%) (Fig. 3D). Similarly, 
no significant difference in postoperative 30-day mortality 
was detected (RR = 1.01; 95% CI, 0.73 to 1.42; P = 0.93, 
I2 = 0%) in six studies [15, 17, 18, 20, 22, 23] that com-
prised 10,884 patients (1272 and 9612 who underwent 
MIPD and OPD, respectively) (Fig. 3E).
Short‑term oncological outcomes
Rate of vein resection
Three studies [15, 21, 23] comprising a total of 913 patients 
(228 underwent MIPD and 685 underwent OPD) provided 
data on vein resection; our analysis revealed no difference 
in the vein resection rate (RR = 0.96; 95% CI 0.76 to 1.20; 
P = 0.71, I2 = 0%) (Fig. 4A).
Rate of R0 resection
Eight studies [15–18, 20–23] including 11,192 patients 
(1349 and 9843 underwent MIPD and OPD, respectively) 
provided data regarding the R0 resection rate. We found 
that the R0 resection rate was higher in the MIPD group, 
with low heterogeneity as shown in a random effects 
model (RR = 1.06; 95% CI 1.01 to 1.12; P = 0.02, I2 = 36%) 
(Fig. 4B).
Fig. 1  Flowchart showing the 
protocol of the meta-analysis. 
MIPD minimally invasive 
pancreaticoduodenectomy, OPD 
open pancreaticoduodenectomy, 
PDAC pancreatic duct adeno-
carcinoma
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Harvesting and positivity rate of lymph nodes
The numbers of harvested lymph nodes were measured in 7 
studies [15–18, 20, 21, 23] that included 9575 patients (1279 
who underwent MIPD and 8296 who underwent OPD). 
There was no significant difference in the number of har-
vested lymph nodes between the two groups (MD 0.98; 95% 
CI − 1.32 to 3.27; P = 0.4) (Fig. 4C). The heterogeneity was 
high (I2 = 86%), and a random effects model was adopted. 
Moreover, data regarding lymph node positivity were also 
reported in these studies; the pooled results showed no sta-
tistical difference between the two groups (MD = 0.96; 95% 
CI 0.74–1.26; P = 0.78, I2 = 92%) (Fig. 4D). Our sensitivity 
analysis showed no obvious differences.
Time to starting adjuvant chemotherapy after surgery
Four studies [15, 20–22] gathered data on the time to start-
ing adjuvant chemotherapy after surgery, including a total 
of 10,494 patients (1242 and 9252 underwent MIPD and 
OPD, respectively). The pooled results indicated that the 
time to adjuvant chemotherapy was significantly shorter in 
the MIPD group (MD = − 15.35; 95% CI − 30.33 to − 0.36; 
P = 0.04) (Fig. 4E). The heterogeneity was high (I2 = 98%), 
and a random effects model was adopted.
OS and DFS
DFS data were available in 2 studies [15, 16]. A significantly 
longer DFS was observed in the MIPD group (HR 1.30, 95% 
CI 1.02 to 1.66, P = 0.04, I2 = 0%) (Fig. 5A). Eight studies 
[15, 16, 18–23] investigated OS; their pooled data revealed 
no significant difference between patients who underwent 
MIPD and those who underwent OPD (HR 0.98, 95% CI 
0.95 to 1.02, P = 0.36, I2 = 0%) (Fig. 5B).
Publication bias
Begg’s funnel plot was used to assess any publication bias 
present in the articles. As shown in the funnel plot of OS 
(Fig. 6), no evidence of significant publication bias was 
found.
Discussion
To our knowledge, this is the first meta-analysis designed 
to specifically evaluate the perioperative and oncological 
outcomes of patients with PDAC who underwent MIPD 
and compare the findings with those for patients who under-
went OPD. Overall, the pooled results revealed no signifi-
cant difference in OS between the two groups, although 
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commenced adjuvant chemotherapy sooner after surgery. 
Moreover, we found no significant difference in operative 
time, postoperative complications, 30-day mortality, vein 
resection, number of harvested lymph nodes, or number of 
positive lymph nodes between the two approaches. There 
was a significant improvement in margin-negative resection 
with MIPD, as well as a shorter LOS and a lower intraopera-
tive blood transfusion volume. Thus, our findings suggest 
that the outcomes of MIPD are at least equivalent to, if not 
better than, those of OPD in patients with PDAC.
It was previously thought that operating time would be 
longer with MIPD; this method is certainly challenging and 
has a steep learning curve. A recent retrospective multicenter 
analysis by Wang et al. [24] found that the learning curve for 
MIPD had 3 phases, with peaks evident after the completion 
of 40 and 104 cases. They also concluded that the operative 
time significantly decreased from phase I to phase III and 
was even comparable with that of OPD, consistent with the 
findings of van Hilst et al. [25] and Boone et al. [26]. In 
the present study, no significant difference between the 2 
approaches was observed in terms of operative time. Croome 
et al. [15] excluded 10 patients who underwent MIPD in the 
first 6 months to avoid the early segment of their learning 
curve, which may have introduced bias with regard to our 
pooled results; however, we found no significant change in 
our results when excluding their study from our analysis. 
Therefore, our findings suggest that the operating time for 
MIPD is comparable to that of OPD once the learning curve 
is achieved.
The feasibility and safety of MIPD have been established 
given that enthusiasm for this procedure continues to grow 
quickly. MIPD has the potential to markedly reduce intra-
operative blood loss and transfusion, as well as LOS; these 
attributes were corroborated in our own study. Although 
there were no sufficient data for analyzing intraopera-
tive blood loss, the rate of blood transfusion was lower in 
patients undergoing MIPD in the present study, which ought 
to reflect lower intraoperative blood loss. Allogeneic blood 
transfusion has been confirmed to be an independent nega-
tive predictor of DFS and OS among patients with PDAC 
who underwent PD [27, 28]. Therefore, MIPD may poten-
tially be related to improved survival compared to OPD in 
patients with this disease. A shorter LOS could also translate 
into faster recovery, which may help introduce subsequent 
treatments sooner. LOS is also an important component of 
healthcare costs [29], and whether opting for MIPD can sig-
nificantly reduce such costs over OPD is an important area 
of active investigation [30].
Fig. 2  Comparison of perioperative outcomes between patients who underwent minimally invasive pancreaticoduodenectomy (MIPD) and those 
who underwent open pancreaticoduodenectomy (OPD) for pancreatic duct adenocarcinoma
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In the present study, total and major complications attrib-
uted to MIPD occurred at a similar rate to those attributed 
to OPD, including postoperative pancreatic fistulae, delayed 
gastric emptying, postpancreatectomy hemorrhage, and 
30-day mortality. Other studies have also observed such 
outcomes [25, 31, 32]. Therefore, the minimally invasive 
approach does not appear to alter the risk of severe com-
plications and death compared to OPD. This is highly 
important because most resections are performed to treat 
malignant diseases. Moreover, Stauffer et al. showed that 
major complications may be an independent predictor of 
poorer survival [21]. It is highly probable that major postop-
erative complications would at least delay the administration 
of subsequent chemotherapy or limit the patient’s ability to 
tolerate a full course.
Our study also found that surrogate oncologic indicators 
including the number of resected veins, number of harvested 
lymph nodes, and rate of positive nodes were similar in the 
Fig. 3  Comparison of postoperative and 30-day mortality between patients who underwent minimally invasive pancreaticoduodenectomy 
(MIPD) and those who underwent open pancreaticoduodenectomy (OPD) for pancreatic duct adenocarcinoma
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Fig. 4  Short-term oncological outcomes of patients who underwent minimally invasive pancreaticoduodenectomy (MIPD) and those who under-
went open pancreaticoduodenectomy (OPD) for pancreatic duct adenocarcinoma
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2 groups, although the rate of R0 resection was higher in the 
MIPD group than in the OPD group. MIPD was contraindi-
cated in patients who required vascular resection and recon-
struction in a previous study [33]. However, Croome et al. 
[34] suggested that MIPD with major vascular resection is 
feasible and safe, and it can achieve similar results in terms 
of morbidity and mortality rates as well as of oncologic out-
comes as does OPD with major vascular resection. The latter 
notion is supported by our data. Nevertheless, the acquisition 
of considerable experience for performing OPD both with 
and without vascular resection and for performing MIPD 
without vascular resection is strongly recommended before 
attempting minimally invasive major vein resection and 
reconstruction [35]. Previous studies found that the lymph 
node and margin statuses were significant predictors of DFS 
and OS [21, 36]. Our pooled results revealed that MIPD 
Fig. 5  Long-term oncological outcomes of patients who underwent minimally invasive pancreaticoduodenectomy (MIPD) and those who under-
went open pancreaticoduodenectomy (OPD) for pancreatic duct adenocarcinoma
Fig. 6  Begg’s funnel plot for 
assessing publication bias
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produced oncologic outcomes similar to, or even more 
favorable than, OPD did. Moreover, Stauffer et al. [21] found 
that the proportion of positive lymph nodes in patients who 
underwent MIPD was lower than that in patients who under-
went OPD, and that the negative margin rate was higher; 
however, neither finding was statistically significant. These 
results may indicate that the minimally invasive approach 
allows for complete and adequate lymphadenectomy and 
pancreatic resection as it provides superior and magnified 
views of the tumor.
The primary results of this study showed a significant 
improvement in the time to starting adjuvant chemotherapy 
and in DFS among patients with PDAC who underwent 
MIPD; Conrad et  al. [31] reported similar outcomes in 
their study. According to a recent evaluation of the Euro-
pean Study Group for Pancreatic Cancer, completion of all 
6 cycles of adjuvant chemotherapy following resection of 
PDAC improves OS if the chemotherapy is started within 
12 weeks [37]. Croome et al. [15] reported that the lack 
of chemotherapy within 90 days of surgery was a strong 
predictor of poorer OS; this suggests that the inability to 
initiate or complete chemotherapy in a timely manner will 
ultimately have a negative influence on survival. Our data 
do indicate a longer DFS in the MIPD group than in the 
OPD group, which may reflect the difference in the timing of 
adjuvant treatment initiation. Therefore, we posit that MIPD 
may enhance the ability of patients to receive subsequent 
treatments in a timely fashion after surgery and to complete 
their dosing schedules as well.
Another primary result in our study was the lack of a 
significant difference in OS between the 2 approaches. Chap-
man et al. [22] reported that patients undergoing MIPD had 
a noticeably longer median survival time than did those 
undergoing OPD (19.8 vs. 15.6  months) as well as an 
improved OS (HR 0.85, 95% CI 0.69 to 10.3) after adjust-
ing for patient- and tumor-related characteristics; these find-
ings were similar to those of Croome et al. [15] and Conrad 
et al. [31]. Furthermore, Stauffer et al. [21] also found that 
the 5-year survival rates of patients who underwent MIPD 
and OPD were 32% and 15.34%, respectively. However, the 
differences in OS in these aforementioned studies were not 
significant. It remains to be determined whether MIPD can 
result in a significantly different OS among patients with 
PDCA as additional patients are accrued and follow-up 
periods are lengthened. Nevertheless, in our opinion, one 
of the key objectives for achieving superior oncologic out-
comes with existing treatment modalities is to improve the 
ability of patients to receive both complete tumor resection 
and chemotherapy, and we believe that MIPD is a realistic 
method to meet this objective.
Two other meta-analyses that were similar to ours were 
identified in our search [8, 38]. Although the stated aims 
of both were to assess LPD versus OPD in patients with 
PDAC, they included patients with ampullary carcinoma, 
some benign tumors, and even chronic pancreatitis in addi-
tion to those with PDACs. Moreover, the pooled results 
of short-term oncological outcomes such as R0 resection 
and number of lymph nodes retrieved were different from 
ours, since we only included patients with PDAC. Even 
though their findings regarding OS were similar to ours, 
they found 4 of the studies that were also included in our 
analysis [15, 20–22] to be heterogeneous (although we did 
not), whereas 8 other studies were not heterogeneous in 
their analyses (as consistent with our data). Consequently, 
their meta-analyses may prevent achieving objective con-
clusions regarding the oncologic safety of MIPD.
There were some limitations to our study that should 
be taken into account when considering the results. First, 
all included studies were retrospective and conducted in 
high-volume hospitals. Numerous studies have shown that 
hospital volume is significantly correlated with the inci-
dence of perioperative outcomes [24]. Kantro et al. [20] 
reported that the 30-day mortality rate for patients who 
underwent MIPD was higher in low-volume hospitals than 
in high-volume institutions; therefore, there was a risk of 
selection bias even though such confounders could not be 
avoided. Second, the numbers of patients in some of the 
studies were too small, leading to low-power analyses. 
Third, only one of the included studies [16] compared 
RPD and OPD, which may have introduced bias because 
robotic and laparoscopic approaches have substantial dif-
ferences, and the number of patients who underwent RPD 
was small and accounted for a small proportion in the 
analysis of results regarding the R0 resection rate, num-
ber of harvested lymph nodes, rate of positive nodes, and 
OS. However, the results and heterogeneity for all these 
variables showed no significant change after exclusion of 
the study comparing RPD and OPD. Nevertheless, some 
of our conclusions, particularly those pertaining to RPD, 
should be interpreted with caution. In the future, when 
more data are available, subgroup analysis should be per-
formed to determine whether is any difference between the 
laparoscopic and robotic approaches. Finally, the hetero-
geneity in some of the results was high. Although we con-
ducted sensitivity analyses, the results and heterogeneity 
were barely changed. Thus, some of our results should be 
interpreted with caution. Overall, additional prospective 
and multicenter randomized controlled trials with longer 
follow-up periods are warranted to compare the oncologi-
cal outcomes of MIPD and OPD.
In conclusion, the results of our meta-analysis indicate 
that MIPD appears to be safe and feasible with perioperative, 
short-term, and long-term outcomes that are similar to those 
of OPD in the setting of PDAC. Moreover, MIPD may also 
provide advantages such as lower transfusion rates, higher 
rates of margin-negative resection, shorter time to starting 
2284 Surgical Endoscopy (2021) 35:2273–2285
1 3
adjuvant chemotherapy, and longer DFS when compared to 
OPD in patients with PDAC.
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